Analysis of influential factors for the failure of tigecycline in the treatment of multidrug-resistant <italic style="font-style: italic">Acinetobacter baumannii </italic>pneumonia

SUN Guoxian; XU Yuan; LIU Weili; HOU Hongling; YIN Wenxing

doi:10.6039/j.issn.1001-0408.2022.22.18

您当前的位置：

首页 >

文章列表页 >

Analysis of influential factors for the failure of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia

更新时间：2023-02-22

- Analysis of influential factors for the failure of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia
- ZHONGGUO YAOFANG Vol. 33, Issue 22, Pages: 2775-2778(2022)
- 作者机构：
  
  1.扬州大学附属医院临床药学科，江苏扬州　225001
  2.扬州大学附属医院重症医学科，江苏扬州　225001
  3.扬州大学附属医院神经内科，江苏扬州　225001
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2022.22.18
  CLC： R978.1⁺4
- Published：30 November 2022，
  
  Received：03 August 2022，
  
  Revised：22 September 2022，
扫描看全文
孙国先,徐媛,刘微丽等.替加环素治疗多重耐药鲍曼不动杆菌肺炎失败的影响因素分析 ^Δ[J].中国药房,2022,33(22):2775-2778.

SUN Guoxian,XU Yuan,LIU Weili,et al.Analysis of influential factors for the failure of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia[J].ZHONGGUO YAOFANG,2022,33(22):2775-2778.
孙国先,徐媛,刘微丽等.替加环素治疗多重耐药鲍曼不动杆菌肺炎失败的影响因素分析 ^Δ[J].中国药房,2022,33(22):2775-2778. DOI： 10.6039/j.issn.1001-0408.2022.22.18.

SUN Guoxian,XU Yuan,LIU Weili,et al.Analysis of influential factors for the failure of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia[J].ZHONGGUO YAOFANG,2022,33(22):2775-2778. DOI： 10.6039/j.issn.1001-0408.2022.22.18.

摘要

目的

探讨替加环素治疗多重耐药鲍曼不动杆菌（MDRAb）肺炎失败的影响因素，为合理使用替加环素提供依据。

方法

回顾性收集我院ICU 2020年8月至2022年6月选择替加环素治疗MDRAb肺炎患者的病例资料，依据疗效将患者分为治疗失败组和治疗成功组，记录并比较两组患者的基本信息、急性生理学和慢性健康状况评价Ⅱ（APACHE-Ⅱ）评分、实验室指标、用药相关信息。采用Logistic回归分析法对替加环素治疗MDRAb肺炎失败的影响因素进行分析。

结果

共有102例使用替加环素治疗MDRAb肺炎的患者，其中治疗成功组有71例，治疗失败组有31例。与治疗成功组比较，治疗失败组患者APACHE-Ⅱ评分更高（

＜0.05），凝血功能异常和共病种类≥2种的例数更多（

＜0.05）。替加环素治疗后，治疗失败组降钙素原显著高于治疗成功组（

＜0.05）。Logistic回归分析显示，导致替加环素治疗MDRAb肺炎失败的独立危险因素为凝血功能异常、APACHE-Ⅱ评分≥20分（

＜0.05），首剂负荷是保护性因素（

＜0.05）。

结论

APACHE-Ⅱ评分≥20分和凝血功能异常的MDRAb肺炎患者，给予替加环素治疗失败的可能性大；替加环素首剂负荷给药治疗MDRAb肺炎，疗效更优。

Abstract

OBJECTIVE

To explore the factors influencing the failure of tigecycline in the treatment of multidrug-resistant

Acinetobacter baumannii

（MDRAb） pneumonia， and to provide a basis for the rational use of tigecycline.

METHODS

The information of patients with MDRAb pneumonia who were treated with tigecycline in the ICU of our hospital during Aug. 2020-Jun. 2022 were collected retrospectively. The patients were divided into treatment failure group and treatment success group according to the curative effect. The basic information， acute physiology and chronic health evaluation Ⅱ （APACHE-Ⅱ） score， laboratory indicators， and medication-related information were recorded and compared between 2 groups. Logistic regression analysis was conducted for analyzing the influential factors inducing the failure of tigecycline in the treatment of MDRAb pneumonia.

RESULTS

A total of 102 cases of MDRAb pneumonia received tigecycline therapy， with 71 in the treatment success group and 31 in the treatment failure group. Compared with the treatment success group， the patients in the treatment failure group had higher APACHE Ⅱ score （

＜0.05）， and more cases with abnormal coagulation function and comorbidities ≥2 types （

＜0.05）. After the treatment of tigecycline， procalcitonin level of the treatment failure group was significantly higher than that of the treatment success group （

＜0.05）. Logistic regression analysis showed that the independent risk factors for the failure of tigecycline in the treatment of MDRAb pneumonia included abnormal coagulation function and APACHE-Ⅱ score ≥20 （

＜0.05）； doubling the first dose was a protective factor （

＜0.05）.

CONCLUSIONS

In patients with MDRAb pneumonia with APACHE-Ⅱ score ≥20 and abnormal coagulation function， tigecycline therapy is more likely to fail； doubling the first dose of tigecycline has better efficacy in the treatment of MDRAb pneumonia.

关键词

替加环素多重耐药鲍曼不动杆菌肺炎治疗失败影响因素

Keywords

multidrug-resistant Acinetobacter baumanniipneumoniatreatment failureinfluential factor

references

王亚，朱华栋. 鲍曼不动杆菌的耐药机制及其治疗进展[J]. 中华急诊医学杂志，2017，26（7）：834-836.

陈佰义，何礼贤，胡必杰，等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中华医学杂志，2012，92（2）：76-85.

卫生部. 医院感染诊断标准：试行[J]. 中华医学杂志，2001，81（5）：314-320.

《抗菌药物临床试验技术指导原则》写作组. 抗菌药物临床试验技术指导原则：附件：抗菌药物立题原则建议[J]. 中国临床药理学杂志，2014，30（9）：857-858.

国家卫生健康委员会. 替加环素临床应用评价细则：国卫办医函〔2018〕822号[EB/OL].（2018-09-21）[2022-07-28]. http：//www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?idhttp://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id＝95f65ca473b44746b24590e94468

b8ff.

RAMIREZ J，DARTOIS N，GANDJINI H，et al. Ran-domized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipene- mcilastatin for treatment of hospital-acquired pneumonia[J]. Antimicrob Agents Chemother，2013，57（4）：1756-1762.

BAI X R，LIU J M，JIANG D C，et al. Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia （HAP）：a meta-analysis of cohort studies[J]. J Chemother，2018，30（3）：172-178.

LIU B，LI S，LI H T，et al. Outcomes and prognostic factors of tigecycline treatment for hospital-acquired pneumonia involving multidrug-resistant Acinetobacter baumannii[J]. J Int Med Res，2020，48（4）：300060520910917.

陈敏英，刘紫锰. 临床重症与药学超说明书用药专家共识[J]. 今日药学，2020，30（8）：505-515.

赵智慧，王晓莉，马志强. 超说明书使用替加环素联合头孢哌酮舒巴坦治疗多重耐药鲍曼不动杆菌肺炎的临床研究[J]. 中国药房，2017，28（2）：201-204.

BHAVNANI S M，RUBINO C M，HAMMEL J P，et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline[J]. Antimicrob Agents Chemother，2012，56（2）：1065-1072.

孟伟. 替加环素治疗危重患者多重耐药菌感染的临床疗效观察[D]. 济南：山东大学，2013.

赵梦雅，段美丽. 血乳酸和乳酸清除率与降钙素原联合检测对脓毒症患者病情严重程度及预后评估的临床意义[J]. 中华危重病急救医学，2020，32（4）：449-453.

张明，王瑾，王睿，等. 替加环素致凝血功能障碍文献分析[J]. 中国新药杂志，2021，30（3）：285-288.

SALIBA R，PAASCH L，EL SOLH A. Tigecycline atte-nuates staphylococcal superantigen-induced T-cell prolifera-tion and production of cytokines and chemokines[J]. Immunopharmacol Immunotoxicol，2009，31（4）：583-588.

金晶，吴伟平，林德. 替加环素联合9种抗菌药物对碳青霉烯耐药细菌的抗菌作用[J]. 中国卫生检验杂志，2018，28（11）：1281-1284.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of influential factors for purchasing quantity changes in the procurement varieties of the first batch of drug centralized procurement

The characteristics and influencing factors of medicine cost for orthopedic surgery patients in hospitals of Shanxi province

Analysis of DRG grouping effect and influential factors of hospitalization cost of diabetic patients

Analysis of the burden of polypharmacy and its influencing factors among elderly tuberculosis patients in Guizhou province

我国省级基本药物增补情况与影响因素分析

Related Author

LIU Yuxin

WEN Xiaotong

DUAN Fengran

WANG Yue

YANG Ying

MAO Zongfu

LI Weipeng

SHANG Nan

Related Institution

Dong Fureng Institution of Economic and Social Development， Wuhan University

Global Health Institute， Wuhan University

School of Public Health， Wuhan University

School of Nursing， Tongji Medical College of Huazhong University of Science and Technology

School of Pharmacy， Shanxi Medical University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Analysis of influential factors for the failure of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia

DOI：10.6039/j.issn.1001-0408.2022.22.18

摘要

Abstract

关键词

Keywords

references